Ischemic HF (multicentre)

Fulfill inclusion & exclusion criteria

Written informed consent

Selection period: Standardized treatment 10 ± 3 days

Central randomization

QSYQ group (n=320)
Standardized treatment + QSYQ (1 packet Tid)

Placebo group (n=320)
Standardized treatment + placebo (1 packet Tid)

Study visits: 1, 3, 6, 9, 12 month with/without extension

Clinical evaluation

Efficacy

6MWT, composite endpoint, BNP, echocardiography (e.g. LVEF), cardiothoracic ratio, NYHA classification, Quality of life, TCM four diagnostic information, blood lipids

Safety

Physical examination, laboratory test, adverse events

Comprehensive assessment

Process data

Efficacy and safety

Unstable HF

Stable HF

Corresponding treatment

6 month trial medication

Selection period: Standardized treatment 10 ± 3 days

Written informed consent

Selection period: Standardized treatment 10 ± 3 days

Written informed consent

Selection period: Standardized treatment 10 ± 3 days

Written informed consent

Selection period: Standardized treatment 10 ± 3 days

Written informed consent